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Primary liver cancer is the fifth and seventh most com-
mon cancer in men and women, respectively, and hepato-
cellular carcinoma (HCC), the most common histological 
subtype, accounts for 70–85% of cases (Jemal et al., 2011). 
HCC develops almost exclusively in the context of liver 
diseases associated with chronic inflammation. For this rea-
son, liver cirrhosis, a consequence of many chronic liver 
diseases such as viral hepatitis, alcohol-induced hepatitis, or 
non–alcohol-induced hepatitis, is the main risk factor for 
HCC (Fattovich et al., 2004). Previous findings using ge-
netically engineered mouse models (GEMMs) indicate that 
continuous rounds of hepatocyte injury, necrosis, inflam-
mation-induced cell death, and subsequent compensatory 
proliferation are essential for liver cancer initiation and pro-
motion (Farazi and DePinho, 2006). This is supported by the 
fact that during progression of chronic liver disease, HCC 
risk increases (Fattovich et al., 2004).
Although some improvement in the management of 
HCC has been achieved in the last 30 years, beneficial 
treatment is only possible at early stages by local ablative 
therapies, resection, or transplantation (Villanueva et al., 
2013). Long-term prognosis after surgical resection of 
HCC remains poor, owing to the high rate of metasta-
sis or de novo recurrence. Systemic chemotherapies and 
targeted therapies have failed in the treatment of HCC 
(Villanueva et al., 2013). Besides prevention and treatment 
of the causative liver diseases, early diagnosis, identification 
of high-risk patients, and prevention of malignant trans-
formation are the most promising approaches. The critical 
step to identify biomarkers and develop effective preven-
tive therapies is a better understanding of the mechanisms 
responsible for cancer initiation. The pathways most fre-
quently involved are p53, Wnt/β-catenin, mTOR, TGF-β, 
Ras, Rb, HGF/c-Met, and IGF1. Transcription factors 
such as NF-κB, c-Myc, and AP-1 play an important role 
in HCC development (Liu et al., 2002; Wagner and Ne-
breda, 2009; Jain et al., 2010; He and Karin, 2011; Nault 
and Zucman-Rossi, 2011).
Human hepatocellular carcinomas (Hccs), which arise on a background of chronic liver damage and inflammation, express 
c-Fos, a component of the AP-1 transcription factor. using mouse models, we show that hepatocyte-specific deletion of c-Fos 
protects against diethylnitrosamine (dEn)-induced Hccs, whereas liver-specific c-Fos expression leads to reversible premalig-
nant hepatocyte transformation and enhanced dEn-carcinogenesis. c-Fos–expressing livers display necrotic foci, immune cell 
infiltration, and altered hepatocyte morphology. Furthermore, increased proliferation, dedifferentiation, activation of the dnA 
damage response, and gene signatures of aggressive Hccs are observed. Mechanistically, c-Fos decreases expression and activ-
ity of the nuclear receptor LXrα, leading to increased hepatic cholesterol and accumulation of toxic oxysterols and bile acids. 
the phenotypic consequences of c-Fos expression are partially ameliorated by the anti-inflammatory drug sulindac and largely 
prevented by statin treatment. An inverse correlation between c-FoS and the LXrα pathway was also observed in human Hcc 
cell lines and datasets. these findings provide a novel link between chronic inflammation and metabolic pathways important 
in liver cancer.
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The AP-1 transcription factor is a dimeric complex 
composed of members of the Jun (c-Jun, JunB, JunD) and 
Fos (c-Fos, FosB, Fra1, Fra2) families of bZIP proteins. Com-
ponents of AP-1 including c-Jun and c-Fos are important 
regulators of tumor development (Eferl and Wagner, 2003). 
In human HCC, both c-Jun and c-Fos are highly expressed, 
and genome-wide expression analysis of human HCCs re-
vealed that AP-1 is at the center of an oncogenic signaling 
network in a subset of HCC with poor prognosis (Yuen et 
al., 2001; Liu et al., 2002; Lee et al., 2006). Mouse models for 
liver cancer have further established the importance of AP-1 
in liver pathology and HCC (Bakiri and Wagner, 2013). In 
the diethylnitrosamine (DEN)-induced liver cancer model, 
mice with liver-specific inactivation of c-Jun have signifi-
cantly fewer tumors because of p53-dependent apoptosis 
of tumor cells (Eferl et al., 2003). Consistently, inhibition of 
JNKs, which activate and stabilize c-Jun, leads to reduced 
proliferation and increased sensitization toward apoptosis in 
HCC models in vivo and in vitro (Sakurai et al., 2006; Hui 
et al., 2007; Wagner and Nebreda, 2009; Seki et al., 2012). 
c-Jun is specifically required for mouse liver tumorigenesis 
during cancer initiation, and we have shown that c-Jun pro-
motes preneoplastic cell survival by regulating c-Fos– and 
SIRT6-dependent expression of survivin (Eferl et al., 2003; 
Min et al., 2012). The cancer-promoting function of c-Jun 
was also shown in mouse models for HBV- and HCV-related 
liver tumorigenesis (Machida et al., 2010; Trierweiler et al., 
2016). Finally c-Jun promotes hepatocyte survival in exper-
imental models of hepatitis, ER stress, and activated β-cat-
enin–induced liver damage (Hasselblatt et al., 2007; Fuest et 
al., 2012; Trierweiler et al., 2012).
The role of c-Fos in HCC development is less well 
defined. Studies in human HCC cell lines indicate that 
c-Fos is important for cell migration (Fan et al., 2013), and 
ectopic expression of c-Fos in immortalized human he-
patocytes increased cell proliferation (Güller et al., 2008). 
We recently documented how distinct AP-1 dimers reg-
ulate the expression of PPARγ in the liver in models of 
nonalcoholic fatty liver disease (Hasenfuss et al., 2014b), a 
condition associated with obesity and an established risk 
factor for HCC (Michelotti et al., 2013). Accumulation of 
cholesterol, especially free cholesterol and cholesterol de-
rivatives such as oxysterols and bile acids (BAs), promotes 
hepatotoxicity, oxidative stress, inflammation, and even he-
patocyte transformation (Tabas, 2002; Ikonen, 2006; Jusakul 
et al., 2011; Wang et al., 2013). The nuclear receptor and 
transcription factor LXRα (Nr1h3), which is activated by 
oxysterols, is essential for cholesterol homeostasis. In the 
liver, LXRα forms transcriptional heterodimers with reti-
noid X receptors (RXRs) and mediates cholesterol removal 
by promoting both cholesterol conversion to BAs and cho-
lesterol excretion to the bile (Calkin and Tontonoz, 2012). 
As a result, Lxrα knockout mice display altered hepatic cho-
lesterol and BA metabolism, with cholesterol accumulation 
and impaired hepatic function (Peet et al., 1998; Zhang et 
al., 2012). The BA receptor FXR (Nr1h4) is another im-
portant nuclear receptor and RXR dimerization partner es-
sential for lipid and BA homeostasis (Calkin and Tontonoz, 
2012). Mice lacking FXR have increased BAs, liver damage, 
inflammation, and late-onset liver tumors, all prevented by 
restoring BA homeostasis through BA-sequestering agents 
or intestinal FXR expression (Kim et al., 2007; Yang et al., 
2007; Degirolamo et al., 2015).
In this study, we show that hepatocyte-specific expres-
sion of c-Fos leads to reversible premalignant transformation 
of hepatocytes, with mRNA signatures resembling human 
HCCs. Importantly, using the DEN experimental HCC 
model, we demonstrate that c-Fos is essential for hepato-
cyte transformation and HCC development. Mechanistically, 
c-Fos negatively regulates LXRα expression, which affects 
cholesterol and BA homeostasis.
rESuLtS
Hepatic c-Fos expression leads to 
premalignant transformation
To investigate the role of c-Fos expression in liver physiology 
and carcinogenesis, a hepatocyte-specific doxycycline-
switchable mouse model was used. LAP-tTA; col1a1 :Tet -O 
-fosFlag double-transgenic mice are referred to as c-foshep-tetOFF 
mice, and single-transgenic littermates were used as controls 
throughout the study. Expression of c-Fos was switched on at 
the age of 3 wk by doxycycline removal. Although endogenous 
c-Fos is undetectable in control livers, hepatocyte-specific 
expression of Flag-tagged ectopic c-Fos was observed by 
immunohistochemical staining (IHC; Fig.  1  A), quantitative 
RT-PCR (qRT-PCR; Fig. 1 B), and Western blot (Fig. S1 A). 
No ectopic c-Fos mRNA was detected in any other tissue 
tested (Fig. S1 B). c-foshep-tetOFF mice had a median survival of 
5 mo (Fig. 1 C). Therefore, changes in liver physiology were 
analyzed at up to 4 mo of c-Fos expression. The first histological 
observation was single-cell necrosis with surrounding immune 
cell infiltrates, mainly periportal, at 1 mo (Fig. S1 C). These 
lesions progressed over time to multiple necrotic foci at 3 and 
4 mo (Fig. S1 C). Increased serum alanine aminotransferase 
(ALT), a marker for liver damage, was observed at 2 mo of 
c-Fos expression (Fig. 1 D), whereas elevated serum γ-glutamyl 
transferase and decreased albumin and blood urea nitrogen, all 
indicative of liver dysfunction, were observed at 4 mo (Fig. S1 D). 
Macroscopically, progressive hepatosplenomegaly was observed 
(Fig. 1 E), whereas body weight was not affected (Fig. S1 E). 
An altered growth pattern of hepatocytes was visible at 4 mo 
of c-Fos expression, with trabecular proliferation and double as 
well as poly nuclei (Fig. 1 F). In addition, although the controls 
showed the expected central vein localization of glutamine 
synthetase (GS), mutant livers displayed diffuse cytoplasmic 
staining, indicative of disturbed liver zonation (Fig.  1  F). 
Moreover, scattered positive staining for the dedifferentiation 
markers CK19 and Sox9 was apparent (Fig. 1 F) at as early as 
2.5 mo of c-Fos expression (Fig. S1 F; see also Fig. 9 E). These 
results indicate that hepatocyte-specific c-Fos expression leads to 
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Figure 1. Phenotypic consequences of hepatocyte-specific c-Fos expression. Ectopic expression of c-Fos was achieved in 3-wk-old mice by doxycy-
cline removal. Mice were analyzed at 1, 2, 3, and 4 mo of c-Fos expression. (A) Representative Flag IHC in liver sections from c-foshep-tetOFF and control mice 
2 mo after doxycycline removal.(B) qRT-PCR analyses of c-fos in different tissues. Bar graphs represent mean ± SD; n = 2/3; mean expression in controls 
set to 1; ***, P ≤ 0.001 by Student’s t test. (C) Kaplan–Meier curve (n = 5/cohort); 5 mo = median survival in mutants. *, P ≤ 0.05. (D and E) Serum ALT (D; 
n = 4; 12; 3; 9/3; 11; 3; 6) and liver/body and spleen/body weight ratio (E; n = 4; 5; 3; 10/3; 5; 3; 7) upon c-Fos expression. Plots represent mean ± SD. ***, 
P ≤ 0.001 by two-way ANO VA. (F) Representative liver pictures, H&E, and IHC for GS, CK19, and Sox9 in c-foshep-tetOFF and controls at 4 mo. (G) Normalized 
enrichment scores at 4 mo ectopic c-Fos expression relative to controls (RNA-seq, n = 3/cohort) compared with human HCC molecular classes and relevant 
gene signatures by GSEA. False discovery rate (FDR) q-values are indicated on the right side. n.a., not applicable, as the published gene signature was uni-
directional (only enriched genes). Hatched bars highlight inverse correlations computed with up-regulated (red) or down-regulated (green) gene sets. (H) 
Representative IHC for AFP and β-catenin in c-foshep-tetOFF and controls at 4 mo. (A, F, and H) Bars: (F, left) 1 cm; (A, F [right], and H) 100 µm.
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altered hepatocyte morphology, necrosis, and a dedifferentiated 
phenotype indicative of premalignant transformation.
Fos-expressing mouse livers exhibit molecular 
characteristics of human Hccs
Genome-wide transcription profiling using RNA-seq of 
liver mRNA at 4 mo of c-Fos expression was compared by 
gene set enrichment analysis (GSEA) with the well-estab-
lished molecular classifications of human HCC (reviewed 
in Hoshida et al., 2010; van Malenstein et al., 2011; Pin-
yol et al., 2014). Notably, a significant positive correlation 
was observed with the hepatoblast (HB) subtype of human 
HCC with poor prognosis (Fig. 1 G), in which c-Fos/AP-1 
was previously shown to be up-regulated and located in the 
center of an oncogenic signaling network (Lee et al., 2006). 
c-Fos–expressing gene expression profiles also significantly 
correlated with published HCC gene signatures, in partic-
ular the subtypes G3 (Boyault et al., 2007), S1 (Hoshida 
et al., 2009), the proliferative class (Chiang et al., 2008), 
and pediatric hepatoblastoma (Cairo et al., 2008; Fig. 1 G). 
These gene signatures are all characteristic of dedifferentia-
tion, fetal liver–like gene expression, high proliferation, and 
aggressiveness (Hoshida et al., 2010; van Malenstein et al., 
2011; Pinyol et al., 2014). We also observed a significantly 
positive correlation, with a 590-gene signature differen-
tially expressed across mouse primary hepatic progenitor 
cells, HBs, and transformed adult hepatocytes (Holczbauer 
et al., 2013), whereas a significant inverse correlation was 
computed with signatures derived from healthy livers 
(Hsiao et al., 2001) or the well-differentiated and less ag-
gressive S3 HCC subclass (Hoshida et al., 2009). A large 
fraction of these correlations could already be computed in 
RNA-seq profiles of livers expressing c-Fos at 2 mo (Fig. 
S1 G). These results imply that c-Fos expression leads to 
molecular characteristics of hepatocyte dedifferentiation 
and premalignant transformation. Consistent with dediffer-
entiation and premalignant transformation, α-fetoprotein 
(AFP) positivity and nuclear β-catenin were also observed 
(Fig.  1  H). Because c-Fos mutant mice showed dramat-
ically reduced survival as a result of hepatic dysfunction, 
we speculate that c-Fos–expressing mice die before these 
premalignant cells progress to HCCs.
Liver carcinogenesis is enhanced by c-Fos expression
To circumvent the lethality induced by sustained c-Fos ex-
pression, the DEN-induced experimental carcinogenesis 
paradigm was applied to adult mice, with c-Fos expression 
restricted to tumor initiation (Fig. 2 A). In this setting, control 
mice very rarely developed HCCs (Bakiri and Wagner, 2013). 
However, when ectopic c-Fos expression was induced for a 
short period during DEN-induced tumor initiation, tumor 
development at 7 mo was significantly increased (Fig. 2 A). 
qRT-PCR analyses revealed increased c-Fos expression in tu-
mor-bearing livers, whereas ectopic c-Fos was not expressed 
(Fig. S2 A). These data strongly imply a promoting function of 
c-Fos operating during the early events of malignant hepato-
cyte transformation and HCC development.
dEn-induced Hcc formation requires c-Fos expression
We next applied the DEN-induced mouse liver cancer model 
to mice with hepatocyte-specific knockout of c-Fos (c-fosΔli). 
Mice with conditional alleles (c-fosf/f) combined with the 
Alfp-Cre transgene were used to delete c-fos specifically 
in hepatocytes (Kellendonk et al., 2000; Fleischmann et al., 
2003). DEN was injected in 2-wk-old pups to allow efficient 
tumor formation. Whereas all control mice developed mul-
tiple HCCs 8 mo later, c-fosΔli mice hardly developed any 
visible tumor (Fig. 2 B and Fig. S2 B). Histological analyses 
documented a significantly reduced number and size of foci 
in these mutants, which mainly displayed nodular prolifera-
tion and almost no HCC. PCR analyses of genomic DNA 
from liver and tumor tissue confirmed deletion of c-fos in 
c-fosΔli mice (Fig. S2 C). Moreover, DEN-induced DNA ad-
ducts were increased in c-fosΔli mice (Fig. S2 D), indicating 
that decreased tumor load in c-Fos mutants is not caused by 
decreased carcinogenic DEN metabolites.
Genome-wide transcription profiling using RNA-seq 
was performed using liver mRNA from c-fosΔli mice 48 h 
after DEN injection. Strikingly, several of the gene sets that 
correlated with Fos-overexpressing livers were also found en-
riched in the dataset from DEN-injected c-fosΔli mice but in 
the opposite direction. Most notably, whereas the S3-HCC 
subclass and healthy liver–specific genes were positively cor-
related with the c-fosΔli expression dataset, the HCC-HB 
subtype, the S1 and proliferative HCC subclasses, and the 
gene set characteristic of dedifferentiated/transformed he-
patocytes were negatively correlated (Fig.  2 C). These data 
further confirm the association between c-Fos expression 
and malignant hepatocyte transformation during HCC and 
establish that c-Fos is not only sufficient to induce malig-
nant transformation of hepatocytes, but is also required for 
HCC development in vivo.
Liver inflammation and genotoxic stress induced by c-Fos
The c-Fos–induced hepatomegaly and premalignant trans-
formation was accompanied by an increase in the number 
of Ki67-positive nuclei indicative of proliferation (Fig. 3, A 
and B). S139 phosphorylation of histone H2AX (γH2AX), a 
surrogate marker of DNA damage (Kinner et al., 2008), and 
increased p53- and p21-positive nuclei (Fig. 3, A and B) were 
also observed, indicating that the DNA damage response 
(DDR) was activated. Although necrosis was apparent, no ob-
vious hepatocyte apoptosis was detected by cleaved caspase 3 
IHC (not depicted). Significantly more immune cells were 
detected in the liver, in particular myeloperoxidase-positive 
granulocytes (Fig. 3, C and D). Flow cytometry analyses con-
firmed the accumulation of CD45-positive cells in the liver 
(Fig. S2 E) and the specific increase in Gr1+ cells at 2 mo, 
whereas NK and B cells were reduced (Fig. 3 E). Increased 
circulating leukocytes and granulocytes were also observed in 
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Figure 2. c-Fos expression promotes and is essential for Hcc development. (A) 5-wk-old c-foshep-tetOFF and controls were injected with 100 mg/kg 
DEN, while c-Fos expression was maintained from 3 to 9 wk. Representative liver pictures and histology 7 mo after DEN. (Right) Macroscopic and histo-
logical tumor quantification at 7 mo (n = 6/5). (B) 15-d-old c-fosΔli and c-fosf/f littermates were injected with 25 mg/kg DEN. Representative liver pictures 
and H&E 8 mo later.. (Right) Histological tumor quantification in c-fosΔli and controls 8 mo after DEN (n = 14/10). (A and B) Bars: (top) 1 cm; (bottom) 100 
µm. T, tumor. Bar graphs represent mean ± SD; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 by Student’s t test. (C) Normalized enrichment scores 48 h after DEN 
injection in 8-wk-old c-fosΔli mice relative to controls (RNA-seq, n = 3/cohort) compared with human HCC molecular classes and relevant gene signatures 
by GSEA. False discovery rate (FDR) q-values are indicated on the right side. n.a., not applicable, as the published gene signature was unidirectional (with 
only enriched genes). n.s., not significant, as only one out of the two signatures published for the gene set was enriched in the GSEA. Hatched bars highlight 
inverse correlations computed with up-regulated (red) or down-regulated (green) gene sets. Note that the enrichment scores in c-fosΔli livers are inverse 
orientation, compared with the analysis of c-foshep-tetOFF livers presented in Fig. 1 G and Fig. S1 G.
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Figure 3. c-Fos–dependent proliferation, ddr, and inflammation. (A) Representative IHC pictures for Ki67, S139 phosphorylation of histone H2AX 
(γH2AX), p53, and p21 in c-foshep-tetOFF and controls at 4 mo. (B) Quantification of Ki67- and γH2AX-positive hepatocytes at different time points (n = 4; 5; 
3; 7/3; 5; 3; 6 and 4; 4; 2; 4/5; 5; 3; 7) and of p21- and p53-positive hepatocytes at 4 mo (n = 4/5). (C) Representative IHC pictures for CD45 and myelop-
eroxidase (MPO) at 4 mo. (D) Quantification of CD45-positive cells in liver sections (n = 3; 5; 4/3; 5; 4). (E) Immune cell subtypes in the liver at 2 mo (flow 
cytometry, n = 6/8). (F) Blood cell count of white blood cells (WBC), lymphocytes (LYM), and granulocytes (GRA) at the indicated time points of ectopic c-Fos 
expression (n = 4; 7; 6; 8/3; 6; 7; 6). Bars, 100 µm. Bar graphs and plots represent mean ± SD; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ns, not significant by 
Student's t test or two-way ANO VA.
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the blood at later time points (Fig. 3 F), consistent with he-
patic immune cell infiltration and increased spleen size. Several 
pro-inflammatory and pro-oncogenic pathways are activated 
in the livers of c-foshep-tetOFF mice, as indicated by increased 
phosphorylation of Stat3, Jnk1/2, and Akt (Fig. S2 F), likely 
as a response to increased inflammation and genotoxic stress. 
These data imply that c-Fos–induced liver inflammation, he-
patocyte proliferation, and DDR activation are early events.
We next examined the early events occurring after 
DEN injection in the livers of c-Fos gain- and loss-of-func-
tion GEMMs. 8-wk-old c-foshep-tetOFF mice allowed to express 
c-Fos for 5 wk were injected with DEN and analyzed 48 h 
later. Similar to our observations when c-Fos was expressed 
for 1 mo in the absence of DEN (Figs. 1 and 3), serum ALT 
and hepatocyte apoptosis were not changed (Fig. S3 A). Short-
term ectopic c-Fos expression combined with DEN appeared 
to have little effect on immune cell infiltration or prolifera-
tion (Fig. 4, A and B). However, despite comparable γH2AX 
counts, p53- and p21-positive nuclei were increased (Fig. 4, C 
and D), indicating that increased DDR likely contributes to 
tumorigenesis when c-Fos expression is combined with DEN.
Deletion of c-Fos in hepatocytes did not affect serum 
ALT or cell death under basal conditions or 48 h after DEN 
injection (Fig. S3 B), and c-Fos also had little impact on im-
mune cell infiltration after DEN injection (Fig. 4 E). How-
ever, c-fosΔli mice showed increased γH2AX-positive nuclei 
and reduced compensatory proliferation after DEN-in-
duced liver damage (Fig.  4, F and G), possibly accounting 
for decreased tumor load.
We next investigated whether c-Fos is necessary to 
maintain the premalignant phenotype and took advantage of 
the tetracycline control of c-Fos expression in c-foshep-tetOFF 
mice. c-Fos expression was induced for 4 mo, and the mice 
were subsequently put back on doxycycline to repress c-Fos 
expression. 2 mo later, c-Fos expression in c-foshep-tetOFF re-
verted mice was comparable with that of controls, and ec-
topic c-Fos was undetectable (Fig. S3 C). Furthermore, no 
hepatosplenomegaly was observed (Fig. S3 D), and serum 
ALT and blood cell counts were comparable with those of 
control mice (Fig. S3, E and F). Histological analyses con-
firmed normal liver morphology with no Ki67-, CK19-, or 
γH2AX-positive hepatocytes and no immune cell infiltration 
(Fig. 4 H and Fig. S3 G). The c-foshep-tetOFF reverted mice were 
viable and appeared healthy more than 6 mo after turning off 
c-Fos expression (not depicted). These results demonstrate 
that liver damage, inflammation, hepatocyte proliferation, 
and preneoplastic transformation induced by c-Fos expres-
sion are reversible and that c-Fos is essential to maintain the 
premalignant phenotype.
Hepatic metabolic pathways are affected by c-Fos
We next analyzed the three gene expression profiles ob-
tained by RNA-seq using Ingenuity Pathway Analysis. The 
10 top regulated pathways common to all datasets revealed 
a potential Fos-dependent regulation of metabolic pathways, 
particularly the ones connected to cholesterol and fatty acid 
(FA) metabolism. In particular, the LXR/RXR pathway was 
down-regulated upon c-Fos expression and up-regulated in 
c-fos–deficient mice (Fig. 5 A). GSEA confirmed that genes in 
cholesterol and FA biosynthesis were repressed in c-foshep-tetOFF 
mice and enriched in c-fos–deficient mice (Fig. 5 B).
Liver metabolites were next analyzed by nuclear 
magnetic resonance (NMR) spectroscopy. Increased cho-
lesterol species were observed in the livers of c-foshep-tetOFF 
mice relative to controls, whereas triglycerides (TGs) and 
FAs were not affected (Fig. 5 C). Hepatic cholesterol ac-
cumulation in c-foshep-tetOFF mice was confirmed by a 
colorimetric assay, which also indicated that the ratio be-
tween cholesterol species was unaffected (Fig.  5  D). On 
the other hand, serum cholesterol was reduced at 4 mo 
of hepatic c-Fos expression (Fig. S4 A), with a decreased 
esterified/free cholesterol ratio (Fig. S4 B), and restored in 
the c-foshep-tetOFF reverted mice (Fig. S4 C). These results 
demonstrate that cholesterol accumulation in hepatocytes 
is a phenotypic consequence of increased c-Fos expression.
LXrα-mediated cholesterol accumulation 
in Fos-expressing livers
The nuclear receptor LXRα (Nr1h3) is a major regulator of 
cholesterol homeostasis responsible for cholesterol elimina-
tion from the cell (Calkin and Tontonoz, 2012). qRT-PCR 
analyses of genes involved in cholesterol homeostasis and FA 
and TG synthesis, including bona fide LXRα target genes, 
were performed. Several LXRα target genes such as abcg5, 
abcg8, fasn, and acaca were significantly down-regulated at 1 
mo of c-Fos expression (Fig. 6, A and B). Consistent with the 
Ingenuity analysis, reduced expression of genes involved in 
cholesterol synthesis was observed at 2 mo (Fig. 6 C), indicat-
ing compensatory down-regulation. No significant changes 
in expression of LXRα target genes could be observed in 
c-fos–deficient or reverted livers (Fig. S4, D and E).
Oxysterols, which are cholesterol metabolites and natu-
ral ligands for LXRα, were next analyzed by mass spectrom-
etry. Total and free oxysterols were significantly increased in 
livers of c-foshep-tetOFF mice (Fig. 6 D, and Fig. S4 F, and Table 
S1), consistent with increased cholesterol and decreased ex-
pression of the Abcg5/Abcg8 transporter, which promotes 
cholesterol excretion from hepatocytes into bile, and further 
indicating that reduced activity of LXRα is not caused by 
lack of ligands. Cyp7a1, the rate-limiting enzyme for primary 
BA synthesis, is also modulated by LXRα in mice and was 
decreased at 2 mo of c-Fos expression (Fig. 6 A and Fig. S4 
G). However, hepatotoxic primary BAs (CA, CDCA, and 
αMCA) were significantly increased in the liver (Fig. 6 E and 
Table S1), which could be explained by the overall increase 
in cholesterol. On the other hand, hepatoprotective taurine 
conjugates (TDCA and TUD CA) were reduced (Fig. 6 E), 
consistent with reduced mRNA expression of Baat and 
Scl27a5, two enzymes responsible for BA–amino acid con-
jugation (Fig. S4 G). BAs were also increased in serum of 
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Figure 4. c-Fos–dependent early carcinogenic events and phenotype reversibility. (A–D) Quantification of CD45-positive cells (A; n = 5/5) and 
Ki67-positive (B; n = 5/5), γH2AX-positive (C; n = 4/5), and p53-positive (n = 4/5) and p21-positive (D; n = 4/5) hepatocytes in liver sections from 8-wk-old 
c-foshep-tetOFF and control mice 48 h after DEN. (E–G) Quantification of CD45-positive (E; n = 8; 6/8; 5) and BrdU-positive (F; n = 4; 7/3; 6) cells around the 
central vein (CV) and γH2AX-positive hepatocytes (G; n = 4/5) in liver sections from 8-wk-old c-fosΔli and control mice untreated (0) and 48 h after DEN. 
(A–G) Plots represent mean ± SD; *, P ≤ 0.05; ***, P ≤ 0.001 by Student’s t test. (H) Ectopic expression of c-Fos was allowed during 4 mo and then stopped 
by administration of doxycycline. Representative liver histology (H&E) and IHC (Ki67, CD45, CK19, and γH2AX) from c-foshep-tetOFF and controls 2 mo after 
switching off c-Fos expression. Bars, 100 µm.
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Figure 5. Metabolic pathways are regulated by c-Fos in the liver. (A) Ingenuity canonical pathway analyses. The 10 top affected canonical path-
ways in each condition are shown (n = 2/3/3/cohort). (B) Normalized enrichment scores for each indicated genotype and condition derived from GSEA 
and focused on lipid metabolism pathways (RNA-seq, n = 2; 3; 3/cohort). False discovery rate (FDR) q-values are indicated on each bar. (C) Relative 
change in liver cholesterol species, TGs, and FAs identified by NMR in c-foshep-tetOFF (1 and 2 mo of c-Fos expression; n = 3; 5/cohort) and c-fosΔli (48 h 
after DEN; n = 5/cohort) mice. Control groups were set to 1.(D) Cholesterol species in liver tissue of c-foshep-tetOFF and control mice at 4 mo of c-Fos 
expression measured by a colorimetric method (n = 7/6). (C and D) Bar graphs represent mean ± SD;*, P ≤ 0.05; ***, P ≤ 0.001 by Student’s t test.
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c-foshep-tetOFF mice (Fig. 6 F) reflecting both the hepatic in-
crease in toxic BA species and liver damage. These results in-
dicate that c-Fos expression affects LXRα-mediated control 
of cholesterol homeostasis, leading to compensatory reduced 
expression of genes involved in cholesterol synthesis and the 
accumulation of potentially toxic cholesterol species and 
derivatives in the liver.
Inhibition of LXrα expression by c-Fos
A notable down-regulation of hepatic LXRα mRNA was 
found in c-foshep-tetOFF mice (Fig. 7, A and B). This effect is 
likely cell autonomous to hepatocytes, as it was also observed 
in primary hepatocytes isolated from FostetON mice and in-
duced to express c-Fos by addition of doxycycline to the 
culture medium (Fig. 7 C). Consistently, reduced mRNA of 
some LXRα target genes was also observed (Fig. 7 C). Al-
though the mRNA of PPARγ, a direct c-Fos target gene 
(Hasenfuss et al., 2014b), was up-regulated in primary hepato-
cytes (Fig. 7 C) as well as in c-fos–expressing livers (Fig. 7 A 
and Fig. S4 H), mRNA expression of the BA receptor FXR 
(encoded by Nr1h4) was also found to be increased (Fig. 7 A 
and Fig. S4 H), indicating possible regulation by c-Fos or, as 
previously reported (Zhang et al., 2004), by PPARγ. No con-
sistent changes in mRNA expression of other nuclear recep-
tors, such as PPARα/δ or RXRs, were observed in RNA-seq 
or qRT-PCR analyses (Fig. 7 A and Fig. S4 H).
Decreased Lxrα protein was already detectable at 1 mo 
in hepatic protein extracts from c-foshep-tetOFF mice (Fig. 7 D), 
consistent with reduced LXRα target genes and decreased 
LXRα pathway activity. LXRα protein expression was 
comparable to controls in c-fos–deficient livers under basal 
conditions. However, LXRα protein was significantly up-reg-
ulated in c-fos–deficient livers 2 wk after DEN-induced 
carcinogenesis (Fig. 7 E).
The Srebfs/Srebps transcription factors are also in-
volved in cholesterol homeostasis and FA metabolism. GSEA 
revealed down-regulation of Srebf target genes (Horton et 
al., 2003) in c-fos–expressing livers, whereas these genes were 
induced in DEN-treated c-fos–deficient livers (Fig. S4 I). Al-
though Srebf1 mRNA was reduced in c-fos–expressing livers 
at the 2-mo time point (Fig. 6 B), consistent with its reported 
transcriptional modulation by LXRα, increased cleaved (ac-
tive) Srebf1 protein was detected, in particular at the late 
time point (Fig. S4 J). In the same samples, cleaved (active) 
Srebf2 protein was decreased, whereas Srebf2 mRNA ap-
peared unchanged (Fig. S4, J and K). These results suggest that 
c-Fos–dependent alterations in LXR/RXR activity caused 
by decreased expression of LXRα are likely responsible for 
the observed metabolic changes.
Inhibiting inflammation by sulindac treatment
The contribution of inflammation to the complex pheno-
typic changes induced by hepatic c-Fos expression was ex-
plored next. Control and c-foshep-tetOFF mice were treated with 
the COX1/2 inhibitor sulindac for 2 mo starting at 2 mo of 
c-Fos expression (Fig. 8 A). Sulindac had no effect on hepatic 
expression of total or ectopic c-Fos (Fig. S5 A). Increased liver 
size, serum ALT, and serum BA were still apparent in sulin-
dac-treated mutant mice (Fig.  8, B and C). However, liver 
histology revealed normalized numbers of Ki67, reduced 
CD45-positive cells, and numerous hepatocytes positive for 
the dedifferentiation markers CK19 and Sox9 and γH2AX 
(Fig. 8, E and F). In addition, whereas serum cholesterol ap-
peared to be normalized (Fig. S5 B), liver cholesterol species 
were still elevated in sulindac-treated mutant mice (Fig. 8 G). 
Consistently, mRNA expression of LXRα and most LXRα 
target genes was significantly reduced (Fig. 8 H).
These results suggest that hepatic inflammation contrib-
utes to sustaining hepatocyte proliferation upon c-Fos expres-
sion but has little contribution to c-Fos–dependent alterations 
in LXR/RXR activity, hepatic cholesterol accumulation, acti-
vation of DDR, and hepatocyte preneoplastic transformation.
Statin treatment partially reverses the c-Fos–
dependent hepatic phenotype
The contribution of cholesterol and BA metabolism to the 
phenotype was next assessed using an inhibitor of the HMG-
CoA reductase (HMG CR) atorvastatin (in short, statin). 
HMG CR catalyzes the conversion of HMG-CoA to me-
valonate, an early step in cholesterol biosynthesis. Although 
cholesterol synthesis pathway activity was overall decreased 
(Figs. 5 A and 6 C), Hmgcr was up-regulated in the livers of 
c-foshep-tetOFF mice at 2 mo (Fig. S5 C), indicating that statin 
treatment might be effective. Additionally, besides decreasing 
circulating cholesterol and increasing intestinal excretion of 
cholesterol and BA (Parker et al., 2013), atorvastatin is re-
ported to increase hepatic mRNA expression of Cyp7a1, 
Abcg5, and Abcg8 in wild-type mice (Fu et al., 2014). 
c-foshep-tetOFF mice were subjected to statin treatment for 2 
wk, starting at 2 mo of c-Fos expression (Fig. S5 D). A smaller 
cohort of littermate controls was processed in parallel. No 
changes in total or ectopic c-Fos expression were observed 
in statin-treated mice (Fig. S5 E). Although statin treatment 
moderately affected serum ALT (Fig. 9 A), serum BAs were 
decreased to control levels in treated mutants (Fig. 9 B). Sta-
tin decreased circulating cholesterol and low-density lipopro-
tein (LDL) cholesterol in controls, as expected (Lawman et 
al., 2004; Parker et al., 2013), but did not further decrease 
these parameters in mutant mice (Fig.  9 C and Fig. S5 F). 
Consistent with a previous study (Parker et al., 2013), sta-
tin did not affect total hepatic cholesterol (Fig. 9 C). Impor-
tantly, statin increased hepatic mRNA expression of Abcg5, 
Abcg8, Cyp7a1, and Hmgcs1 in all treated groups, with the 
levels of Abcg5 and Abcg8 in statin-treated mutants reach-
ing those of untreated controls (Fig. 9 D). Although hepatic 
Ki67- and CD45-positive cells were slightly diminished, no 
AFP-positive hepatocytes could be detected (Fig. S5 G), and 
significantly fewer hepatocytes expressed CK19 and Sox9 by 
qRT-PCR (Fig. 9 D) and IHC (Fig. 9 E) upon statin treat-
ment. Furthermore, γH2AX-, p53-, and p21-positive hepato-
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Figure 6. Metabolic gene expression and cholesterol derivatives in c-foshep-tetoFF mice. (A–C) qRT-PCR analyses of genes involved in cholesterol 
homeostasis (A), FA and TG (B), and cholesterol (C) synthesis in liver of c-foshep-tetOFF and controls at 1 and 2 mo of c-Fos expression (n = 3/5); mean 
expression in each control group set to 1. (D and E) Free and total oxysterol (D) and BA (E) species in liver extracts from c-foshep-tetOFF at 4 mo of c-Fos 
expression (n = 5/cohort) determined and quantified by MS. Names of oxysterol and BA species are listed in Table S1. (F) Serum BAs (colorimetry) at the 
indicated time points of c-Fos expression (n = 9;3;12/11;4;8). Plots and bar graphs represent mean ± SD; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 by two-way 
ANO VA or Student’s t test.
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Figure 7. regulation of LXrα expression by c-Fos. (A) Relative expression of the indicated nuclear receptors, including Nr1h3 encoding for LXRα, by 
RNA-seq in c-foshep-tetOFF mice at 2 and 4 mo of ectopic c-Fos expression; (n = 2; 3/cohort) and in c-fosΔli mice 48 h after DEN (n = 3/cohort). Bar graphs rep-
resent mean fold changes (log2); # indicates significance after multiple testing corrections. (B) qRT-PCR analyses of Lxrα in total liver tissue of c-foshep-tetOFF 
and control mice at 1, 2, and 4 mo of c-Fos expression. Mean expression in controls set to 1; n = 5; 5; 7/5; 5; 7. (C) qRT-PCR analyses of FostetON primary 
hepatocytes (n = 4 mice/culture) induced to express c-Fos in vitro during 48 h. Expression in untreated cells set to 1. (D) Immunoblot analyses of total liver 
lysates from c-foshep-tetOFF at 1 wk and 1, 2, and 4 mo of c-Fos expression. (Right) Immunoblot quantification normalized to vinculin (n = 3; 7; 6; 12/2; 8; 9; 
12). (E) LXRα immunoblot of liver lysates from c-fosΔli untreated (0 h), 48 h, and 2 wk after DEN injection. (Right) Immunoblot quantification normalized to 
vinculin (n = 2; 9; 5/2; 9; 5). Molecular mass is indicated in kilodaltons. (B–E) Bar graphs represent mean ± SD; *, P ≤ 0.05; ***, P ≤ 0.001 by Student’s t test.
1399JEM Vol. 214, No. 5
cytes were notably decreased in statin-treated c-foshep-tetOFF 
mice (Fig. 9, E and F; and Fig. S5 G).
These results suggest that the c-Fos–dependent DDR 
activation and preneoplastic transformation of hepatocytes 
are likely caused by decreased expression of the Abcg5/Abcg8 
sterol transporter and LXR/RXR target genes and by the 
subsequent alterations in cholesterol and BA metabolism.
Pathway conservation in human liver cells
Using the Cancer Cell Line Encyclopedia of the Broad Insti-
tute, an inverse correlation of c-FOS expression with LXRα 
and its target genes was observed in human HCC cell lines 
(Fig. 10 A) and confirmed by qPCR analyses comparing the 
c-Fos low-expressing HepG2 to the high-expressing Huh7 
and SNU354 HCC cell lines (Fig. 10 B). A significant negative 
correlation between c-FOS and LXRα target genes (FASN, 
ABCG8, ABCG5) was also computed in the gene expression 
dataset of the HB subtype of human HCC (Fig. 10 C). These 
correlations suggest that the conclusions drawn from analyz-
ing GEMMs are likely relevant for human HCCs. We next at-
tempted to define the connection between c-FOS and LXRα 
using human cells. PPARγ, a direct c-Fos/AP-1 target gene, 
is up-regulated in mouse hepatocytes expressing c-Fos (Has-
enfuss et al., 2014b; Fig. 7 C and Fig. S4 H). In rat primary 
hepatocytes and mouse livers, activation of PPARα/γ was re-
ported to decrease LXRα/RXR activity (Yoshikawa et al., 
2003). This was also observed in primary human hepatocytes 
and the HepaRG hepatoma cell line (Rogue et al., 2011), in 
which treatment with PPARγ agonists notably decreased the 
expression of ABCG5, ABCG8, and CYP7A1 (Fig. 10 D). 
Decreased mRNA of ABCG5, ABCG8, and CYP7A1, and 
to a lesser extent, LXRα and FASN, was also observed in 
HepG2 cells treated with the PPARγ agonist pioglitazone 
(Fig.  10 E), whereas c-FOS, PPARγ, and FXR were unaf-
fected and the PPARγ target gene FABP1 was up-regulated 
(Fig. S5 H). Increased PPARγ in c-Fos–expressing hepato-
cytes is therefore likely to be responsible for decreased LXRα 
expression and activity. Whether decreased LXRα expression 
and activity in liver cells occurs through direct binding of 
PPARγ to the LXRα promoter, as shown in human macro-
phages (Chinetti et al., 2001; Laffitte et al., 2001), or rather, 
as proposed by Yoshikawa et al. (2003), through competitive 
reduction of LXR/RXR dimers, remains to be addressed.
dIScuSSIon
GEMMs are essential for advancing the molecular under-
standing of the basic mechanisms of liver diseases (Bakiri and 
Wagner, 2013). Here we show for the first time that hepato-
cyte-specific expression of c-Fos leads to liver inflammation, 
hepatocyte proliferation, DDR activation, and premalignant 
transformation, which depends on sustained c-Fos expres-
sion. When c-Fos expression is experimentally switched off, a 
complete regression of the phenotype is observed. However, 
when combined with a potent mutagen, such as DEN, to 
provide a second pro-oncogenic signal, c-Fos promotes HCC 
development. Importantly, carcinogenesis experiments using 
loss-of-function GEMMs show that c-Fos is not just suffi-
cient, but essential for HCC development.
Mechanistically, hepatocyte-specific c-Fos expression 
leads to hepatic cholesterol accumulation, likely as a result 
of reduced expression and activity of the nuclear recep-
tor LXRα, which is essential for cholesterol homeostasis 
(Peet et al., 1998; Calkin and Tontonoz, 2012; Zhang et al., 
2012). Accumulation of cholesterol and toxic cholesterol 
derivatives (such as oxysterols and primary BAs), DDR 
activation, and subsequent inflammation and hepatocyte 
proliferation are the initiators of the premalignant pheno-
type in c-foshep-tetOFF mice (Fig. 10 F).
A significant correlation with several human HCC 
signatures characteristic of poorly differentiated, aggressive 
tumors, such as the S1 and G3 and the proliferative classes 
(Boyault et al., 2007; Chiang et al., 2008; Hoshida et al., 2009, 
2010; van Malenstein et al., 2011; Pinyol et al., 2014), was 
identified using RNA-seq profiles of c-Fos–expressing mu-
rine livers. The correlation with the specific HB subtype of 
human HCCs with poor prognosis identified by Lee et al. 
(2006) is particularly compelling. Network-based analyses re-
vealed high Fos/AP-1 activity in this subtype, and AP-1 was 
proposed as the main oncogenic driver (Lee et al., 2006). Our 
data experimentally support this hypothesis, as we observed 
not only a strong positive correlation with the HB subtype 
in livers from the c-foshep-tetOFF mice, but also a significant 
inverse correlation in the tumor-resistant, hepatocyte-specific 
c-Fos knockout livers. This inverse correlation pattern of Fos- 
expressing and Fos-deficient livers was also observed with the 
HCC classification signatures and signatures characteristic of 
dedifferentiated/transformed or healthy livers (Hsiao et al., 
2001; Cairo et al., 2008; Holczbauer et al., 2013). Besides the 
molecular signatures, necrosis, inflammation, proliferation, 
and dedifferentiation were histologically observed, all consis-
tent with premalignant transformation. c-foshep-tetOFF mice did 
not develop HCC, most likely because of their reduced life-
span. However, when c-Fos expression was restricted to the 
initiation stage of DEN-induced carcinogenesis, liver tumors 
efficiently developed, indicating that c-Fos is a potent inducer 
of hepatocyte transformation.
We previously reported that c-Jun promotes HCC by 
repressing c-Fos expression in hepatocytes, thus modulating a 
SIRT6/Survivin axis and initiating cancer cell survival (Min 
et al., 2012). In the current study, ectopic expression of c-Fos 
in c-Jun–proficient livers leads to hepatocyte proliferation, 
DDR activation, and premalignant transformation, whereas 
c-Fos inactivation conversely decreases DEN-induced he-
patocyte proliferation and carcinogenesis. These new findings 
thus indicate that the functions and pathways controlled by 
c-Fos in liver carcinogenesis are multiple and stage, context, 
and c-Jun/AP-1 dependent.
c-Fos affects the LXR/RXR pathway controlling he-
patic cholesterol. 1 mo of c-Fos expression already leads to 
reduced pathway activity, with a subsequent increase in total 
The functions of c-Fos in hepatocarcinogenesis | Bakiri et al.1400
Figure 8. Phenotypic consequences of inhibiting inflammation in c-foshep-tetOFF mice. (A) Ectopic expression of c-Fos was allowed during 2 mo and 
then combined with sulindac for an additional 2 mo. (B–D) Liver/body weight (B), serum ALT (C), and serum BAs (D) in sulindac-treated c-foshep-tetOFF and 
controls (n = 6/6). (E) Representative IHC for Ki67, CD45, γH2AX, CK19, and Sox9 in sulindac-treated c-foshep-tetOFF and controls. Bars, 100 µm. (F) Quantifi-
cation of CD45-positive cells and Ki67- and γH2AX-positive hepatocytes in liver sections of sulindac-treated c-foshep-tetOFF and controls (n = 6/6). (G) Liver 
cholesterol species in sulindac-treated c-foshep-tetOFF and controls (n = 6/6). (H) qRT-PCR analyses in total liver tissue from sulindac-treated c-foshep-tetOFF and 
controls (n = 6/6, mean expression in controls set to 1). Bar graphs represent mean ± SD; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.01 by Student’s t test.
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Figure 9. Phenotypic consequences of statin treatment in c-foshep-tetoFF mice. (A–C) Serum ALT (A), serum BAs (B), and serum and liver total choles-
terol (C) in untreated and statin-treated c-foshep-tetOFF and controls (n = 2; 2/4; 6). (D) qRT-PCR analyses in total liver tissue from untreated and statin-treated 
c-foshep-tetOFF and controls (n = 2; 2/3; 5, mean expression in untreated controls set to 1). (E) Representative IHC for Ki67, CD45, γH2AX, p21, CK19, and Sox9 
in untreated and statin-treated c-foshep-tetOFF and controls. Bars, 100 µm. (F) Quantification of CD45-positive cells and Ki67-, γH2AX-, p53-, and p21-positive 
hepatocytes in liver sections of untreated and statin-treated c-foshep-tetOFF and controls (n = 2; 2/4; 6). Bar graphs represent mean ± SD. *, P ≤ 0.05; **, P 
≤ 0.01; ***, P ≤ 0.001 by Student’s t test.
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Figure 10. Liver carcinogenesis by c-Fos in human Hcc and GEMMs. (A) Correlation analyses of c-FOS, NR1H3 encoding for LXRα, and 
LXRα target genes in human HCC cell lines using the Broad Institute Cancer Cell Line Encyclopedia. (B) Relative mRNA expression of c-FOS and 
LXRα target genes in the indicated human HCC cell lines compared with HepG2. Bar graphs represent mean ± SD. (C) Correlation analyses of c-FOS 
and LXRα target genes in the HCC-HB subtype. (D) Correlation analyses of NR1H3 encoding for LXRα, LXRα target genes, and c-FOS in human 
primary hepatocytes from four adult donors treated with the PPARγ agonist rosiglitazone (ROSI) or vehicle (DMSO) for 24 h. Original data were 
deposited by Rogue et al. (2011) in the GEO databank under accession no. GSE27183. (E) Relative mRNA expression of LXRα and its target genes in 
HepG2 cells 24 h after treatment with the PPARγ agonist pioglitazone or vehicle (DMSO). Bar graphs represent mean ± SD; n = 3; DMSO-treated cells 
set to 1. *, P ≤ 0.05; **, P ≤ 0.01; by Student’s t test. (F) Schematic view of c-Fos functions in liver pathology: hepatocyte-specific c-Fos expression 
induced in 3-wk-old mice causes metabolic changes as early as 1 mo later, manifested by inhibition of Lxrα expression and LXR/RXR pathway activ-
ity, leading to liver damage visible by localized necrotic foci. Over time, these changes, together with inflammation, induce hepatocyte proliferation, 
dedifferentiation, and a premalignant phenotype. Within 4 mo of c-Fos expression, hepatic cholesterol, oxysterols, and BAs accumulate, which are 
likely responsible together with liver dysfunction for the death of the mutant mice. When c-Fos expression is combined in adults with a single 
dose of DEN treatment (GOF), HCCs develop 7 mo later; in contrast, the absence of c-Fos (LOF) prevents DEN-induced HCC development when the 
mutagen is applied at 2 wk of age.
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and free cholesterols and oxysterols. Oxysterols are LXRα 
natural ligands; thus, decreased LXRα activity is not caused 
by reduced ligand availability, but rather reduced LXRα 
mRNA and protein. Increased PPARγ in c-Fos–expressing 
hepatocytes likely contributes to decreased LXRα–RXR 
pathway activity, possibly through direct regulation of LXRα 
expression. Because RXR is required as an obligatory het-
erodimerization partner, competitive reduction of LXR/
RXR dimers by PPARγ and FXR might also occur (Yoshi-
kawa et al., 2003; Chan and Wells, 2009). Although systemic 
PPARγ activation is considered rather beneficial in HCC (Yu 
et al., 2010; Wu et al., 2012), ectopic expression of PPARγ in 
wild-type livers by adenoviral delivery enhances hepatocyte 
proliferation, increases liver size, and is deleterious in the con-
text of Pten and Akt inactivation (Panasyuk et al., 2012). De-
fining the contribution of nuclear receptors such as PPARγ, 
RXR, and FXR in HCC downstream or independently of 
AP-1 certainly merits further investigation.
The c-Fos–dependent metabolic alterations are similar 
to those observed in Lxrα knockout mice (Peet et al., 1998; 
Zhang and Friedman, 2012). Lxrα mutants fed a high-cho-
lesterol diet displayed further increased hepatic cholesterol 
and liver dysfunction, although no malignant transfor-
mation was reported. This is surprising because an anti- 
oncogenic function for LXRα in cancer cell lines has been 
documented (Mehrotra et al., 2011; Lo Sasso et al., 2013). 
Consistent with our observations in c-Fos–expressing liv-
ers, LXRα promoted the differentiation of human liver 
progenitor cells (Chen et al., 2014). In a subset of human 
HCC tissue samples in which oxysterols and cholesterol 
were elevated, LXRα mRNA and LXR target gene ex-
pression were found to be significantly reduced (Lu et al., 
2013). This uncoupling between LXR activity and oxys-
terol accumulation, which is also apparent in the livers of 
c-foshep-tetOFF mice, was attributed to impaired sterol catab-
olism and efflux pathways, a metabolic adaptation of tumor 
cells to oxysterol-induced cytotoxicity (Lu et al., 2013). 
Consistently, we computed an inverse correlation between 
c-Fos and LXRα target genes in human HCC cell lines and 
in the HCC-HB subtype, indicating that our findings in 
mouse models are likely relevant to human HCC.
Cholesterol is essential for proliferating cells, but an 
overload of intracellular cholesterol, in diseases such as athero-
sclerosis and Niemann–Pick type C, is cytotoxic and affects 
plasma membrane, ER, lysosomes, and mitochondria (Tabas, 
2002; Feng et al., 2003; Ikonen, 2006; Ibrahim et al., 2011). 
Cholesterol derivatives such as oxysterols and BAs are hepato-
toxic, genotoxic, pro-oxidative, proinflammatory, and carcino-
genic (Perez and Briz, 2009; Jusakul et al., 2011; Wang et al., 
2013). Oxysterols and primary BAs are increased in c-Fos–
expressing livers, whereas BA conjugation, which results in 
less toxic BA species (Perez and Briz, 2009), is decreased, and 
mRNA expression of the two enzymes catalyzing amino acid 
conjugation to BA is reduced. It is thus tempting to speculate 
that c-Fos/AP-1 might modulate the expression of enzymes 
implicated in BA conjugation and/or detoxification, similar 
to the other AP-1 protein Fra-1 (Hasenfuss et al., 2014a).
Accumulation of oxysterol and BAs, DDR, and liver 
damage combined with hepatic inflammation was evident 
in livers of c-foshep-tetOFF mice. Short-term treatment with 
atorvastatin largely prevented the deleterious consequences 
of c-Fos expression, in particular DDR activation and the 
early signs of preneoplastic transformation. Although long-
term statin treatment of c-fos mutant mice might provide 
additional insights, these data strongly support our hypothe-
sis, that deregulation of cholesterol metabolism caused by the 
LXRα–Abcg5/8 sterol transporter axis is crucial in the adverse 
sequence of events after increased c-Fos expression in hepato-
cytes. Preclinical and observational studies indicate that statins, 
widely used to treat hypercholesterolemia, might reduce HCC 
risk in humans (Björkhem-Bergman et al., 2014; Singh et al., 
2014; Kim et al., 2017) and obese mice (Shimizu et al., 2011).
Inflammation is an important pathophysiological mech-
anism for HCC (Fattovich et al., 2004). Expression of c-Fos 
in hepatocytes causes liver inflammation, with granulocytes 
forming the bulk of recruited immune cells. The main trigger 
is likely the chronic damage to hepatocytes caused by accumu-
lation of cholesterol, oxysterols, and primary BAs. Consistently, 
statin treatment decreased inflammatory infiltrates in the liver 
of c-foshep-tetOFF mice, whereas reducing hepatic inflammation 
using sulindac only modestly affected circulating cholesterol and 
LXR target gene expression and had little impact on DDR. In 
hepatocytes, inflammatory stress was reported to affect PPAR/
LXR-controlled intracellular cholesterol homeostasis (Chen et 
al., 2012). We have documented that specific AP-1 dimers con-
trol the transcription of the nuclear receptor PPARγ during 
nutrient overload (Hasenfuss et al., 2014b). Here we show that 
c-Fos/AP-1 links modulation of LXRα nuclear receptor activ-
ity to inflammatory stress (Fig. 10 F). Under stress conditions, 
e.g., liver regeneration, these metabolic alterations might be 
necessary for hepatocyte proliferation. However, chronic liver 
damage, inflammation, and premalignant hepatocyte transfor-
mation predispose to HCC development. Interrupting this 
vicious cycle of chronic inflammation, metabolic alterations, 
and liver damage may constitute a novel targetable pathway 
for HCC prevention and treatment.
MAtErIALS And MEtHodS
Animal procedures
The Col1a1::TetOP-c-fos, LAP-tTA, c-fos floxed, and Alfp-
Cre alleles are described elsewhere (Kistner et al., 1996; Kel-
lendonk et al., 2000; Fleischmann et al., 2003; Briso et al., 
2013). c-foshep-tetOFF and c-fosΔli mice were maintained on a 
C57BL/6 and mixed (C57BL/6 × 129sv) background, re-
spectively, and housed in a specific pathogen–free facility ac-
credited by the American Association for Laboratory Animal 
Care, with food and water ad libitum. Doxycycline (1 g/liter) 
was supplied in the drinking water (Sigma-Aldrich) or in 
food pellets (Research Diet). Mice were treated ad libitum 
with sulindac (Sigma-Aldrich) supplied in the drinking water 
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(180 mg/L). Atorvastatin (TCI Chemicals) was dissolved at 
a final concentration of 20 mg/ml in cyclodextrin (5 mg/
ml; Abmole Bioscience), and mice received daily oral gavage 
for 2 wk (100 mg/kg/d). 2-wk-old pups or 8-wk-old mice 
were injected intraperitoneally with 25 or 100 mg/kg DEN 
(Sigma-Aldrich), respectively. Mice were sacrificed 8 mo after 
DEN injection to monitor HCC development or earlier to 
analyze the acute effects of DEN. BrdU (Sigma-Aldrich) 
was supplied in sucrose-containing (1%) drinking water at a 
concentration of 1 mg/ml. Liver tumor detection by micro–
computed tomography (micro-CT) was performed on anes-
thetized mice after intravenous injection of the iodinated 
contrast agent Iopamiro 300 (Bracco) using a small-animal 
micro-CT system (eXplore Vista PET/CT; GE Healthcare). In 
all experiments, sex-matched littermates were used as controls. 
All animal experiments were performed in accordance with 
institutional, national, and European guidelines for animals 
used in biomedical research and approved by the Spanish Na-
tional Cancer Research Centre (CNIO) Institutional Animal 
Care and Use Committee and the CNIO–Instituto de Salud 
Carlos III Ethics Committee for Research and Animal Welfare.
Blood analyses
Blood was collected by submandibular vein or cardiac (ex-
perimental endpoint) puncture. Complete blood count was 
performed using a hematology analyzer Abacus JunVet (Di-
atron), and serum parameters were measured using a VetScan 
chemistry analyzer (Abaxis) or a Reflovet Plus blood chem-
istry analyzer (Scil Diagnostics) according to the manufactur-
er’s instructions. LDL cholesterol was calculated from total 
cholesterol, high-density lipoprotein cholesterol, and TGs 
using the Friedewald formula.
detection of dnA adducts
10 µg liver DNA was treated with 0.4 M NaOH/10 mM 
EDTA for 10 min at 99°C. Afterward, DNA was dot-blot-
ted on nylon membrane with 0.4 M NaOH. Membrane was 
rinsed in 2× SSC buffer and air-dried. Membrane was blocked 
with 5% skim milk powder in 1× TBS and 0.5% Tween. For 
detection of DNA adducts, membrane was incubated over-
night with mAb to O6-ethyl-2-deoxyguanosine (EM 21; 
Squarix). The blots were incubated with anti–mouse second-
ary HRP-coupled antibodies (GE Healthcare) and developed 
using Luminata Western HRP Substrate (EMD Millipore) 
and Amersham ECL Hyperfilms (GE Healthcare). Loading 
control was performed using methylene blue staining.
Histology and immunohistochemistry
Tissue was fixed in 4% PFA and embedded in either par-
affin or OCT. Hematoxylin and eosin (H&E) staining was 
performed according to standard procedures. For paraffin- 
embedded sections, antigen retrieval was performed using ci-
trate buffer, pH 6.0, in a pressure cooker. PBS supplemented 
with 0.1% Triton X-100, 0.05% Tween, and 1.5% BSA and 
10% serum compatible with the secondary antibody was used 
for antibody dilution. The following antibodies were used for 
IHC: Flag (Cell Signaling Technology), AFP (R&D Systems), 
CK19 (Developmental Studies Hybridoma Bank), MPO 
(Dako), Sox9 (Abcam), Phospho-Ser139-Histone H2AX 
(EMD Millipore), p53 (CNIO mAb unit), p21 (CNIO mAb 
unit), β-catenin (Cell Signaling Technology), CD45 (BD), 
Ki67 (Master Diagnostic), BrdU (AbD Serotec), GS (Sigma- 
Aldrich), and cleaved caspase 3 (Cell Signaling Technology) 
together with matching secondary antibodies from the Vec-
tastain Elite ABC kits (Vector Laboratories). Counterstaining 
was performed using Carazzi’s hematoxylin (Panreac Appli-
Chem). Quantification was performed on digital scans using 
Panoramic Viewer software (3DHI STE CH).
Flow cytometry
Immune cells were isolated from the liver using two-step col-
lagenase perfusion with liver perfusion medium (Gibco) and 
liver digest medium (Gibco) and filtered through a 100-µm 
cell strainer. Hepatocytes were removed by centrifugation at 
50 g. After lysing red blood cells (Sigma-Aldrich), cells were 
incubated with FC-Block (BD) and the following antibodies 
against immune cell surface markers: F4/80-AF647, CD45-
PerCP, and CD45R-APC-Cy7 (BioLegend); CD3-AF700 
(eBioscience); and CD4-PE-Cy7, CD8-PE-Cy5, NK-1.1-PE, 
and Ly-6G/Ly-6C-PerCP-Cy5.5 (BD). Cells were fixed in 2% 
PFA. Data were acquired on a BD LSR II Fortessa and analyzed 
using FlowJo 9.5.3. Live cells were gated for CD45+, and at least 
10,000 individual cells were collected. The different immune 
cell populations in the CD45+ population were gated as fol-
lows: T cells, CD3+, NK1.1−; NK cells, CD3−, NK1.1+; NKT 
cells, CD3+, NK1.1+; CD4+ T cells, CD4+, CD8−; CD8+ T cells, 
CD4−, CD8+; macrophages and monocytes, F4/80+; B cells, 
CD45R+ (B220+); and granulocytes, Gr1+ (Ly-6G/Ly-6C).
Protein isolation and Western blot
Tissue was disrupted using a Precellys device (Bertin Tech-
nologies) in RIPA buffer (50  mM Tris, pH 7.4, 150  mM 
NaCl, 1% NP-40, 0.5% Na-deoxycholate, and 0.1% SDS). 
Protein lysates were quantified using BCA protein assay re-
agent (Thermo Fisher Scientific). For Western blot analysis, 50 
µg protein per sample was loaded. Membranes were blocked 
with 5% BSA or nonfat dry milk in TBS-T. The following 
primary antibodies were used: c-Fos (Santa Cruz Biotech-
nology, Inc.), p-AKT (Cell Signaling Technology), AKT (Cell 
Signaling Technology), p-Stat3 (Cell Signaling Technology), 
Stat3 (Cell Signaling Technology), p-JNK (Cell Signaling 
Technology), JNK (Cell Signaling Technology), Vinculin (Sig-
ma-Aldrich), LXRa (R&D Systems), Srebf1 (Abcam), Srebf2 
(Abcam), and Gapdh (Sigma-Aldrich). Blots were incubated 
with the appropriate secondary HRP-coupled antibody (GE 
Healthcare and Santa Cruz Biotechnology, Inc.) and devel-
oped using Luminata Western HRP Substrate (EMD Mil-
lipore) and Amersham ECL Hyperfilms (GE Healthcare) or 
a ChemiDoc XRS+ imaging system with Image Lab image 
acquisition and analysis software (Bio-Rad).
1405JEM Vol. 214, No. 5
cell culture
Primary mouse hepatocytes were isolated from adult mice and 
cultivated as previously described (Hasenfuss et al., 2014a), 
and doxycycline (Sigma-Aldrich) was dissolved in water and 
added to reach a final concentration of 1 µg/ml. Human 
HepG2, Huh7, and SNU354 cellular carcinoma cell lines were 
maintained in DMEM supplemented with 10% FBS. A final 
concentration of 50 µM of the PPARγ agonist pioglitazone 
(Sigma-Aldrich; dissolved in DMSO) was used to treat HepG2 
cells during 24 h without obvious effect on cell viability.
rnA isolation and rt-Pcr
Total RNA was isolated using TRI Reagent (Sigma-Al-
drich), complementary DNA was synthesized using Ready-
To-Go-You-Prime-First-Strand Beads (GE Healthcare), and 
RT-qPCR used GoTaq RT-qPCR Master Mix (Promega) 
and Eppendorf fluorescence thermocyclers, all according to 
manufacturers’ instructions. The 2ΔΔCT method was used to 
quantify amplified fragments. Expression levels were normal-
ized using at least one housekeeping gene (gapdh and actin). 
Primer sequences are listed in Table S2.
rnA-seq and data analysis
Total RNA was isolated using TRI Reagent (Sigma-Aldrich), 
and RNA integrity was evaluated using an Agilent 2100 Bioan-
alyzer (Agilent Technologies). Samples of RNA integrity score 
>8 were used for RNA-seq. RNA processing was performed 
as described in Illumina’s TruSeq RNA Sample Preparation 
V2 (Part #15026495 Rev B, February 2012). The resulting 
purified cDNA library was applied to an Illumina flow cell 
for cluster generation (TruSeq cluster generation kit v5) and 
sequenced on the Genome Analyzer IIx with SBS TruSeq v5 
reagents according to the manufacturer’s protocols. RNA-seq 
read quality was checked with FastQC (Andrews, 2010). Fastq 
files (Cock et al., 2010) were randomly down-sampled to gen-
erate datasets with similar numbers of reads in all the samples.
The 40-nt single-end reads were aligned to the mouse 
genome (GRCm38/mm10) with TopHat-2.0.4 (Trapnell et 
al., 2012), using Bowtie 0.12.7 (Langmead et al., 2009) and 
Samtools 0.1.16 (Li et al., 2009), allowing two mismatches 
and five multihits. Transcript assembly and estimation of 
abundance were calculated with Cufflinks 1.3.0, using the 
mouse genome annotation dataset GRCm38/mm10 from 
the UCSC Genome Browser (Karolchik et al., 2014). Dif-
ferential expression between genes in both conditions was 
calculated with Cuffdiff (Trapnell et al., 2012), and those 
genes with FPKM expression values lower than 0.05 in both 
conditions were excluded. GSEA was performed to test for 
relevant pathways in the data (Subramanian et al., 2005). Data 
are deposited in NCBI’s Gene Expression Omnibus and are 
accessible through GEO Series accession no. GSE81079.
Metabolite measurements
Liver samples were homogenized using chloroform/isopro-
panol/NP-40 (7:11:0.1). Chloroform was removed from 
the supernatant by vacuum centrifugation (GeneVac). Col-
orimetric cholesterol was measured using a BioVision kit 
(K603-100). NMR was performed at the Spectroscopy 
and Nuclear Magnetic Resonance Spectroscopy Unit. Ox-
ysterols and BAs were measured by Biocrates Life Sciences 
AG (Innsbruck, Austria) using mass spectrometry. The sum 
of all oxysterols species resolved by liquid chromatography/
tandem mass spectrometry (LC-MS/MS) as well as individ-
ual species was analyzed.
For determination of liver metabolite concentrations by 
NMR (Beckonert et al., 2007), dual-phase fractionation using 
extraction in methanol/water/chloroform (1:1:1) was used, 
according to a modified Salomon protocol for the simulta-
neous extraction of polar and apolar metabolites (Tyagi et al., 
1996). In brief, 150–200 mg of tissue samples were disrupted 
in a Precellys 24 device using 3 ml of ice-cold methanol and 
transferred to centrifuge glass tubes (30-ml borosilicate glass 
tubes; Kimble-Chase), where equal volumes of methanol and 
water were sequentially added and vigorously mixed. Frac-
tionation was accelerated by centrifugation at 5,000 g for 15 
min at 4°C, after which the polar and apolar fractions were 
carefully separated and the latter dried by vacuum centrifu-
gation (GeneVac). NMR samples of the apolar fractions were 
prepared by dissolving the dry extract in 500 µl of DCCl3 plus 
300 µl of 20 mM deuterated EDTA, pH 6.0, in D2O/deuter-
ated methanol (1:2) and transferred to 5-mm NMR tubes for 
measurement. High-resolution NMR spectra were registered 
on a Bruker Avance spectrometer operating at 16.4 T (proton 
Larmor frequency of 700 MHz) at 293 K using a TXI probe 
with pulsed field gradient capabilities and equipped with a 
BACS120 sample changer. 1D proton NMR spectra (1dH) 
of the apolar fraction of the liver lysates were recorded using 
a NOE SY pulse sequence (noesygppr1d in Bruker nomen-
clature) using pulse field gradients during the mixing time of 
10 ms and a 2-s recovery delay between consecutive scans. 
256 scans were accumulated using a spectral width of 20 ppm 
centered at 6.37 ppm and with acquisition time of 1.6 s, re-
sulting in an acquisition time of 16.5 min per sample. In ad-
dition, 2D sensitivity-enhanced 1H-13C heteronuclear single 
quantum coherence spectra (2dHC, hsqcetgpsisp2 in Bruker 
nomenclature; Schleucher et al., 1994) were recorded for each 
apolar extract sample (13C natural abundance) with 13C de-
coupling during the 60-ms acquisition time, using an indirect 
(13C) spectral width of 40 ppm centered at 68 ppm, with 35 
indirect increments (complex points), 256 scans per incre-
ment, and 1.2-s recovery delay, resulting in a total acquisition 
time of 6.5 h per 2dHC spectrum. All 1dH free induction de-
cays were processed with exponential multiplication (0.5 Hz 
line-broadening) before Fourier transformation and followed 
by baseline correction using Topspin2.1 (Bruker). The 2dHC 
spectra were processed with NMRPipe (Delaglio et al., 1995) 
using squared cosine window functions in both dimensions, 
and were visualized and analyzed using nmrViewJ (Johnson, 
2004). 1H/13C chemical shifts were referenced to internal deu-
terated methanol (3.36/49.6 ppm). Metabolites in 1dH spectra 
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were quantified from their signal/s integral/s, using integra-
tion regions of variable size that were manually defined to in-
clude all metabolite signals using AMIX3.8 software (Bruker). 
The relative levels of cholesterol and lipids were obtained from 
the maximum intensity of the most intense and best-resolved 
correlations (or combinations thereof) of the different chem-
ical moieties for each metabolite (Vinaixa et al., 2010), as de-
tected in the 2dHC spectra. For example, for assessing total 
cholesterol, the mean of four NMR signals corresponding 
to five methyl groups (C18, C19, C21, and C26 and C27, 
which overlap) was used. Reported metabolite concentrations 
are normalized to total extracted metabolites, as calculated 
from the relative sum of all metabolite signals in 1dH spectra, 
and thus accounting for metabolite level differences resulting 
from different mass of liver tissue and possible differences in 
extraction efficiency as described in Petruzzelli et al. (2014).
To extract metabolites from liver tissue for mass spec-
trometry, samples were homogenized using Precellys with 
100% ethanol containing 0.01% butylated hydroxytoluene. 
For measuring metabolite concentrations, samples were cen-
trifuged, and the supernatant was used for analysis. Biocrates 
Bile Acids kit validated for mouse plasma was used for BA 
quantification. A highly selective reversed-phase LC-MS/MS 
analysis method in negative ion multiple reaction monitoring 
(MRM) detection mode was applied to determine the con-
centrations of BAs. Samples were extracted via dried filter 
spot technique in 96-well plate format. Sample extracts were 
measured by electrospray ionization LC-MS/MS (SCI EX, 
Thermo Fisher Scientific, or Waters Corp.). For highly accu-
rate quantification, seven-point external calibration curves and 
10 stable isotope–labeled internal standards were applied. Data 
of BAs were quantified using the appropriate MS software 
(SCI EX, Analyst; Thermo Fisher Scientific, Xcalibur; and Wa-
ters, MassLynx), and the results were imported into Biocrates 
MetIDQ software for further analysis. Oxysterols, both free 
and esterified, were extracted from samples with methanol 
using a Biocrates kit filter plate. The plate was loaded with an 
internal standard mixture beforehand. The extract was then 
subjected to alkaline hydrolysis to release oxysterols from their 
respective esters. After neutralization, the metabolites were 
determined by ultra-high-performance LC-MS/MS with 
MRM in positive mode using a SCI EX API Qtrap 5500 mass 
spectrometer with electrospray ionization. The assay has been 
validated according to European Medicines Agency guidelines.
Statistics
Data are expressed as mean ± SD. Statistical significance was de-
termined using two-tailed Student’s t test for all bar graphs and 
two-way ANO VA for all plots, except for Kaplan–Meier plots 
where Mantel–Cox log-rank was used. For all experiments, 
values of P < 0.05 were considered statistically significant.
online supplemental material
Fig. S1 shows additional phenotypic consequences of hepato-
cyte-specific c-Fos expression. Fig. S2 shows DEN experi-
ments using c-Fos loss- and gain-of-function mutant mice. 
Fig. S3 includes additional early DEN-induced events in 
c-Fos mutants and illustrates the reversibility of the c-Fos–
induced phenotype. Fig. S4 shows additional liver metabolic 
pathways affected by c-Fos. Fig. S5 depicts data supporting 
the c-Fos–LXRα connection in mouse and human samples. 
Table S1 lists the full and abbreviated name of BAs and oxy-
sterols species determined by mass spectrometry. Table S2 lists 
the specific primers used in this study.
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